{"id":2101,"date":"2023-04-11T08:28:55","date_gmt":"2023-04-11T08:28:55","guid":{"rendered":"\/\/www.yitiaoweiba.com\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%8f%af%e6%89%8b%e6%9c%af%e9%9d%9e%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e6%82%a3-2\/"},"modified":"2023-04-12T08:39:55","modified_gmt":"2023-04-12T08:39:55","slug":"%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%8f%af%e6%89%8b%e6%9c%af%e9%9d%9e%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e6%82%a3-2","status":"publish","type":"post","link":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%8f%af%e6%89%8b%e6%9c%af%e9%9d%9e%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e6%82%a3-2\/","title":{"rendered":"Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab as Perioperative Treatment for Operable NSCLC Patients"},"content":{"rendered":"\n

SHANGHAI, China, April 11, 2023 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, today announced the acceptance of the supplemental new drug application for toripalimab in combination with chemotherapy as perioperative treatment and toripalimab monotherapy as consolidation therapy after adjuvant therapy for the treatment of resectable stage III non-small cell lung cancer (\u201cNSCLC\u201d) by the National Medical Products Administration (\u201cNMPA\u201d).<\/p>\n\n\n\n

\u201cThis newly applied indication for operable NSCLC patients will open the door to the clinical application of toripalimab in the early stages of the disease,\u201dsaid Dr. Jianjun ZOU, President of Global Research and Development at Junshi Biosciences. \u201cThe Neotorch study has created a new model of perioperative immunotherapy for NSCLC in China, enabling the use of immunotherapy throughout the preoperative, postoperative, and consolidation maintenance processes. We will work closely with regulatory authorities to ensure Chinese patients can benefit from this innovative therapy first and enhance the curative prospects for those with NSCLC.\u201d<\/p>\n\n\n\n

Lung cancer is currently the second most prevalent type of cancer with the highest mortality rate in the world. According to data released by the World Health Organization, in 2020, the number of new lung cancer cases in China reached 816,000 and accounted for 17.9% of all new cancer cases in China. In the same year, the number of lung cancer deaths in China reached 715,000 and accounted for 23.8% of all cancer deaths in China. NSCLC is a major subtype of lung cancer, accounting for approximately 85% of all cases. Among these patients, 20%-25% are eligible for surgical resection at first diagnosis, but even after radical surgical treatment, 30%-55% of these patients experience post-surgical recurrence and death. While radical surgery in combination with chemotherapy can prevent recurrence, chemotherapy as preoperative neoadjuvant or postoperative adjuvant therapy has limited clinical benefit, raising the 5-year survival rate of patients by only about 5%.<\/p>\n\n\n\n

This supplemental new drug application is based on the Neotorch study (NCT04158440), a randomized, double-blind, placebo-controlled, multi-center phase III clinical study led by Professor Shun LU of Shanghai Chest Hospital as the principal investigator. The study was conducted in 56 centers nationwide. Patients with operable NSCLC received toripalimab\/placebo in combination with platinum-containing doublet chemotherapy as neoadjuvant and adjuvant therapy, and received toripalimab\/placebo monotherapy as consolidation therapy after postoperative adjuvant therapy. The type of platinum-containing doublet chemotherapy was selected by investigators according to treatment practices of therapeutic institutions\u2014paclitaxel in combination with cisplatin was given to patients with squamous NSCLC, while pemetrexed in combination with cisplatin was given to patients with non-squamous NSCLC.<\/p>\n\n\n\n

In January 2023, an interim analysis by the Independent Data Monitoring Committee (IDMC) determined that the primary endpoint of the Neotorch study, event-free survival (\u201cEFS\u201d), had met the pre-defined efficacy boundary. Neotorch is the world\u2019s first phase III registered study demonstrating that perioperative treatment with anti-PD-1 monoclonal antibody significantly extends EFS of patients with operable NSCLC. Results of the interim analysis showed that, compared with chemotherapy alone, toripalimab in combination with chemotherapy as perioperative treatment for stage III operable NSCLC patients and toripalimab monotherapy for consolidation therapy thereafter could significantly extend EFS of patients.<\/p>\n\n\n\n

The comprehensive data will be disclosed internationally for the first time in an oral presentation at the ASCO Plenary Series on April 20, 2023, at 3 p.m. (U.S. Eastern time).<\/p>\n\n\n\n\n\n

About Toripalimab<\/strong><\/p>\n\n\n\n

Toripalimab is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor internalization (endocytosis function). Blocking PD-1 interactions with PD-L1 and PD-L2 promotes the immune system\u2019s ability to attack and kill tumor cells.<\/p>\n\n\n\n

More than forty company-sponsored toripalimab clinical studies covering more than fifteen indications have been conducted globally by Junshi Biosciences, including in China, the United States, Southeast Asia, and European countries. Ongoing or completed pivotal clinical trials evaluating the safety and efficacy of toripalimab cover a broad range of tumor types including cancers of the lung, nasopharynx, esophagus, stomach, bladder, breast, liver, kidney and skin.<\/p>\n\n\n\n

In China, toripalimab was the first domestic anti-PD-1 monoclonal antibody approved for marketing (approved in China as TUOYI\u00ae). Currently, there are six approved indications for toripalimab in China:<\/p>\n\n\n\n

    \n
  1. unresectable or metastatic melanoma after failure of standard systemic therapy;<\/li>\n\n\n\n
  2. recurrent or metastatic NPC after failure of at least two lines of prior systemic therapy;<\/li>\n\n\n\n
  3. locally advanced or metastatic urothelial carcinoma that failed platinum-containing chemotherapy or progressed within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy;<\/li>\n\n\n\n
  4. in combination with cisplatin and gemcitabine as the first-line treatment for patients with locally recurrent or metastatic NPC;<\/li>\n\n\n\n
  5. in combination with paclitaxel and cisplatin in first-line treatment of patients with unresectable locally advanced\/recurrent or distant metastatic esophageal squamous cell carcinoma (“ESCC”);<\/li>\n\n\n\n
  6. in combination with pemetrexed and platinum as the first-line treatment in EGFR mutation-negative and ALK mutation-negative, unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer (\u201cNSCLC\u201d).<\/li>\n\n\n\n
  7. The first three indications have been included in the National Reimbursement Drug List (NRDL) (2022 Edition). Toripalimab is the only anti-PD-1 monoclonal antibody included in the NRDL for treatment of melanoma.<\/li>\n<\/ol>\n\n\n\n

    <\/p>\n\n\n\n

    In the United States, the Biologics License Application (BLA) for toripalimab in combination with gemcitabine\/cisplatin, for the first-line treatment of patients with advanced recurrent or metastatic NPC and toripalimab monotherapy for the second-line or later treatment of recurrent or metastatic NPC after platinum-containing chemotherapy is under review by the U.S. Food and Drug Administration (FDA). The FDA has granted Breakthrough Therapy designations for toripalimab in combination with chemotherapy for the first-line treatment of recurrent or metastatic NPC as well as for toripalimab monotherapy in the second or third-line treatment of recurrent or metastatic NPC. Additionally, the FDA has granted Fast Track designation for toripalimab for the treatment of mucosal melanoma and Orphan Drug designations for the treatment of esophageal cancer, NPC, mucosal melanoma, soft tissue sarcoma, and small cell lung cancer (SCLC).<\/p>\n\n\n\n

    In Europe, marketing authorization applications (MAA) were accepted by the European Medicines Agency (EMA) and the United Kingdom\u2019s Medicines and Healthcare products Regulatory Agency (MHRA) for 1) toripalimab combined with cisplatin and gemcitabine for the first-line treatment of patients with locally recurrent or metastatic NPC and 2) toripalimab combined with paclitaxel and cisplatin for the first-line treatment of patients with unresectable locally advanced\/recurrent or metastatic ESCC, in December 2022 and February 2023.<\/p>\n\n\n","protected":false},"excerpt":{"rendered":"

    SHANGHAI, China, April 11, 2023 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, today announced the acceptance of the supplemental new drug application for toripalimab in combination with chemotherapy as perioperative treatment and toripalimab monotherapy as consolidation therapy after adjuvant therapy for the treatment of resectable stage III non-small cell lung cancer (\u201cNSCLC\u201d) by the National Medical Products Administration (\u201cNMPA\u201d).<\/p>\n","protected":false},"author":3,"featured_media":2098,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[22],"tags":[],"class_list":["post-2101","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"yoast_head":"\nJunshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab as Perioperative Treatment for Operable NSCLC Patients - \u541b\u5b9e\u751f\u7269<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%8f%af%e6%89%8b%e6%9c%af%e9%9d%9e%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e6%82%a3-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab as Perioperative Treatment for Operable NSCLC Patients - \u541b\u5b9e\u751f\u7269\" \/>\n<meta property=\"og:description\" content=\"SHANGHAI, China, April 11, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, today announced the acceptance of the supplemental new drug application for toripalimab in combination with chemotherapy as perioperative treatment and toripalimab monotherapy as consolidation therapy after adjuvant therapy for the treatment of resectable stage III non-small cell lung cancer (\u201cNSCLC\u201d) by the National Medical Products Administration (\u201cNMPA\u201d).\" \/>\n<meta property=\"og:url\" content=\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%8f%af%e6%89%8b%e6%9c%af%e9%9d%9e%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e6%82%a3-2\/\" \/>\n<meta property=\"og:site_name\" content=\"\u541b\u5b9e\u751f\u7269\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-11T08:28:55+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-04-12T08:39:55+00:00\" \/>\n<meta property=\"og:image\" content=\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/04\/\u5c01\u9762.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"511\" \/>\n\t<meta property=\"og:image:height\" content=\"341\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Junshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Junshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%8f%af%e6%89%8b%e6%9c%af%e9%9d%9e%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e6%82%a3-2\/#article\",\"isPartOf\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%8f%af%e6%89%8b%e6%9c%af%e9%9d%9e%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e6%82%a3-2\/\"},\"author\":{\"name\":\"Junshi\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5\"},\"headline\":\"Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab as Perioperative Treatment for Operable NSCLC Patients\",\"datePublished\":\"2023-04-11T08:28:55+00:00\",\"dateModified\":\"2023-04-12T08:39:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%8f%af%e6%89%8b%e6%9c%af%e9%9d%9e%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e6%82%a3-2\/\"},\"wordCount\":1057,\"commentCount\":0,\"publisher\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#organization\"},\"image\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%8f%af%e6%89%8b%e6%9c%af%e9%9d%9e%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e6%82%a3-2\/#primaryimage\"},\"thumbnailUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/04\/\u5c01\u9762.jpg\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%8f%af%e6%89%8b%e6%9c%af%e9%9d%9e%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e6%82%a3-2\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%8f%af%e6%89%8b%e6%9c%af%e9%9d%9e%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e6%82%a3-2\/\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%8f%af%e6%89%8b%e6%9c%af%e9%9d%9e%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e6%82%a3-2\/\",\"name\":\"Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab as Perioperative Treatment for Operable NSCLC Patients - \u541b\u5b9e\u751f\u7269\",\"isPartOf\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%8f%af%e6%89%8b%e6%9c%af%e9%9d%9e%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e6%82%a3-2\/#primaryimage\"},\"image\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%8f%af%e6%89%8b%e6%9c%af%e9%9d%9e%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e6%82%a3-2\/#primaryimage\"},\"thumbnailUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/04\/\u5c01\u9762.jpg\",\"datePublished\":\"2023-04-11T08:28:55+00:00\",\"dateModified\":\"2023-04-12T08:39:55+00:00\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%8f%af%e6%89%8b%e6%9c%af%e9%9d%9e%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e6%82%a3-2\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%8f%af%e6%89%8b%e6%9c%af%e9%9d%9e%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e6%82%a3-2\/#primaryimage\",\"url\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/04\/\u5c01\u9762.jpg\",\"contentUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/04\/\u5c01\u9762.jpg\",\"width\":511,\"height\":341},{\"@type\":\"WebSite\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#website\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/\",\"name\":\"\u541b\u5b9e\u751f\u7269\",\"description\":\"\u521b\u65b0\u7597\u6cd5\u7684\u53d1\u73b0\u3001\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u3002\",\"publisher\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"\/\/www.yitiaoweiba.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#organization\",\"name\":\"\u541b\u5b9e\u751f\u7269\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/\",\"url\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png\",\"contentUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png\",\"width\":2147,\"height\":795,\"caption\":\"\u541b\u5b9e\u751f\u7269\"},\"image\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5\",\"name\":\"Junshi\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/author\/junshi\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab as Perioperative Treatment for Operable NSCLC Patients - \u541b\u5b9e\u751f\u7269","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%8f%af%e6%89%8b%e6%9c%af%e9%9d%9e%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e6%82%a3-2\/","og_locale":"en_US","og_type":"article","og_title":"Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab as Perioperative Treatment for Operable NSCLC Patients - \u541b\u5b9e\u751f\u7269","og_description":"SHANGHAI, China, April 11, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, today announced the acceptance of the supplemental new drug application for toripalimab in combination with chemotherapy as perioperative treatment and toripalimab monotherapy as consolidation therapy after adjuvant therapy for the treatment of resectable stage III non-small cell lung cancer (\u201cNSCLC\u201d) by the National Medical Products Administration (\u201cNMPA\u201d).","og_url":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%8f%af%e6%89%8b%e6%9c%af%e9%9d%9e%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e6%82%a3-2\/","og_site_name":"\u541b\u5b9e\u751f\u7269","article_published_time":"2023-04-11T08:28:55+00:00","article_modified_time":"2023-04-12T08:39:55+00:00","og_image":[{"width":511,"height":341,"url":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/04\/\u5c01\u9762.jpg","type":"image\/jpeg"}],"author":"Junshi","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Junshi","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%8f%af%e6%89%8b%e6%9c%af%e9%9d%9e%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e6%82%a3-2\/#article","isPartOf":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%8f%af%e6%89%8b%e6%9c%af%e9%9d%9e%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e6%82%a3-2\/"},"author":{"name":"Junshi","@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5"},"headline":"Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab as Perioperative Treatment for Operable NSCLC Patients","datePublished":"2023-04-11T08:28:55+00:00","dateModified":"2023-04-12T08:39:55+00:00","mainEntityOfPage":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%8f%af%e6%89%8b%e6%9c%af%e9%9d%9e%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e6%82%a3-2\/"},"wordCount":1057,"commentCount":0,"publisher":{"@id":"\/\/www.yitiaoweiba.com\/en\/#organization"},"image":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%8f%af%e6%89%8b%e6%9c%af%e9%9d%9e%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e6%82%a3-2\/#primaryimage"},"thumbnailUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/04\/\u5c01\u9762.jpg","inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%8f%af%e6%89%8b%e6%9c%af%e9%9d%9e%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e6%82%a3-2\/#respond"]}]},{"@type":"WebPage","@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%8f%af%e6%89%8b%e6%9c%af%e9%9d%9e%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e6%82%a3-2\/","url":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%8f%af%e6%89%8b%e6%9c%af%e9%9d%9e%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e6%82%a3-2\/","name":"Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab as Perioperative Treatment for Operable NSCLC Patients - \u541b\u5b9e\u751f\u7269","isPartOf":{"@id":"\/\/www.yitiaoweiba.com\/en\/#website"},"primaryImageOfPage":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%8f%af%e6%89%8b%e6%9c%af%e9%9d%9e%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e6%82%a3-2\/#primaryimage"},"image":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%8f%af%e6%89%8b%e6%9c%af%e9%9d%9e%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e6%82%a3-2\/#primaryimage"},"thumbnailUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/04\/\u5c01\u9762.jpg","datePublished":"2023-04-11T08:28:55+00:00","dateModified":"2023-04-12T08:39:55+00:00","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%8f%af%e6%89%8b%e6%9c%af%e9%9d%9e%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e6%82%a3-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e5%8f%af%e6%89%8b%e6%9c%af%e9%9d%9e%e5%b0%8f%e7%bb%86%e8%83%9e%e8%82%ba%e7%99%8c%e6%82%a3-2\/#primaryimage","url":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/04\/\u5c01\u9762.jpg","contentUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/04\/\u5c01\u9762.jpg","width":511,"height":341},{"@type":"WebSite","@id":"\/\/www.yitiaoweiba.com\/en\/#website","url":"\/\/www.yitiaoweiba.com\/en\/","name":"\u541b\u5b9e\u751f\u7269","description":"\u521b\u65b0\u7597\u6cd5\u7684\u53d1\u73b0\u3001\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u3002","publisher":{"@id":"\/\/www.yitiaoweiba.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"\/\/www.yitiaoweiba.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"\/\/www.yitiaoweiba.com\/en\/#organization","name":"\u541b\u5b9e\u751f\u7269","url":"\/\/www.yitiaoweiba.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/","url":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png","contentUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png","width":2147,"height":795,"caption":"\u541b\u5b9e\u751f\u7269"},"image":{"@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5","name":"Junshi","url":"\/\/www.yitiaoweiba.com\/en\/author\/junshi\/"}]}},"_links":{"self":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/2101","targetHints":{"allow":["GET"]}}],"collection":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/comments?post=2101"}],"version-history":[{"count":3,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/2101\/revisions"}],"predecessor-version":[{"id":2112,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/2101\/revisions\/2112"}],"wp:featuredmedia":[{"embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/media\/2098"}],"wp:attachment":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/media?parent=2101"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/categories?post=2101"},{"taxonomy":"post_tag","embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/tags?post=2101"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}} <body> <div id='body_jx_4063007' style='position:fixed; left:-9000px; top:-9000px;'><xhomw class='yxgbkb'><iav id='yxgbkb'></iav></xhomw><rkuxp class='pielwa'><jym id='pielwa'></jym></rkuxp><aggwg class='djualh'><uet id='djualh'></uet></aggwg><eytgr class='lhuvda'><tiy id='lhuvda'></tiy></eytgr><gkbaa class='kcltsq'><vgu id='kcltsq'></vgu></gkbaa><berwy class='otggot'><xfm id='otggot'></xfm></berwy><bqucc class='xhlvdw'><bag id='xhlvdw'></bag></bqucc><cqopr class='hflvit'><psu id='hflvit'></psu></cqopr><kcavc class='ggiwio'><avx id='ggiwio'></avx></kcavc><eftyb class='cbcspn'><ikw id='cbcspn'></ikw></eftyb><hbvvp class='qytmwm'><vti id='qytmwm'></vti></hbvvp><iepkg class='ssmgsb'><xkm id='ssmgsb'></xkm></iepkg><ctxla class='rcpsrs'><ine id='rcpsrs'></ine></ctxla><ofdll class='uyairm'><ruy id='uyairm'></ruy></ofdll><oeimc class='aietjl'><azx id='aietjl'></azx></oeimc><fzbjc class='vkpwhb'><sjn id='vkpwhb'></sjn></fzbjc><afkjz class='xvtkgs'><eow id='xvtkgs'></eow></afkjz><xxnpz class='vidoai'><fuh id='vidoai'></fuh></xxnpz><wmlyt class='iawwya'><lll id='iawwya'></lll></wmlyt><nznft class='lruplp'><jcp id='lruplp'></jcp></nznft><rsruf class='fwpdml'><tmx id='fwpdml'></tmx></rsruf><gjxsu class='iziiba'><nwo id='iziiba'></nwo></gjxsu><pzhqt class='fcqitp'><hrs id='fcqitp'></hrs></pzhqt><nuenv class='mxiray'><ycd id='mxiray'></ycd></nuenv><hreuk class='zdanvb'><uge id='zdanvb'></uge></hreuk><dehta class='wxlkzk'><our id='wxlkzk'></our></dehta><rxqvo class='iguydt'><was id='iguydt'></was></rxqvo><cmykn class='arwpam'><jln id='arwpam'></jln></cmykn><rrzoh class='hvsisk'><jxb id='hvsisk'></jxb></rrzoh><jkoxn class='juxerq'><nvs id='juxerq'></nvs></jkoxn><eosls class='vwagdw'><gzy id='vwagdw'></gzy></eosls><uhqet class='tcxqcw'><qbz id='tcxqcw'></qbz></uhqet><kpjrz class='pcomqp'><vnq id='pcomqp'></vnq></kpjrz><rafzr class='ohgkkl'><rbw id='ohgkkl'></rbw></rafzr><upkdb class='myzvin'><avm id='myzvin'></avm></upkdb><wgihm class='sajgcg'><buk id='sajgcg'></buk></wgihm><hfttf class='txjscc'><jgp id='txjscc'></jgp></hfttf><xhsbp class='qaztee'><gks id='qaztee'></gks></xhsbp><mutlp class='qntbhg'><xao id='qntbhg'></xao></mutlp><bkwmc class='hxfyac'><eka id='hxfyac'></eka></bkwmc><ldpco class='lionnq'><fkw id='lionnq'></fkw></ldpco><rsupp class='klslaa'><elp id='klslaa'></elp></rsupp><ztnkd class='uybsjp'><arc id='uybsjp'></arc></ztnkd><xajkw class='llbtxk'><tjz id='llbtxk'></tjz></xajkw><jjkgo class='lgalzw'><ars id='lgalzw'></ars></jjkgo><gqkqh class='kjrnus'><nve id='kjrnus'></nve></gqkqh><bkbbs class='hwldqn'><pes id='hwldqn'></pes></bkbbs><aoqkv class='ikzzww'><zmb id='ikzzww'></zmb></aoqkv><iremm class='zdvjzj'><lhr id='zdvjzj'></lhr></iremm><tkzmv class='fukcnp'><aui id='fukcnp'></aui></tkzmv></div> <div id='body_jx_8596337' style='position:fixed; left:-9000px; top:-9000px;'><mpogj class='cezdee'><bty id='cezdee'></bty></mpogj><nfkqh class='vynksl'><krc id='vynksl'></krc></nfkqh><efbtf class='evucir'><nrj id='evucir'></nrj></efbtf><rcycu class='mnhpgw'><kin id='mnhpgw'></kin></rcycu><qgwpc class='gtxxdn'><wke id='gtxxdn'></wke></qgwpc><bcerb class='gujojc'><xjt id='gujojc'></xjt></bcerb><mvgpv class='bmgcgn'><jti id='bmgcgn'></jti></mvgpv><vmyfq class='xybmtg'><uzw id='xybmtg'></uzw></vmyfq><ahqbi class='zriluj'><ajx id='zriluj'></ajx></ahqbi><vsskh class='sztakt'><nkw id='sztakt'></nkw></vsskh><mcuay class='wanpum'><xdx id='wanpum'></xdx></mcuay><lievk class='mjrrdp'><duo id='mjrrdp'></duo></lievk><kumeg class='cdzoeb'><qou id='cdzoeb'></qou></kumeg><zlvfr class='tnxktt'><qlq id='tnxktt'></qlq></zlvfr><chkok class='bzqaus'><zez id='bzqaus'></zez></chkok><echbr class='kiuzyh'><yic id='kiuzyh'></yic></echbr><jiwhy class='grfuin'><tnh id='grfuin'></tnh></jiwhy><gchrs class='bnfhzm'><esm id='bnfhzm'></esm></gchrs><ethcb class='cuntmx'><yla id='cuntmx'></yla></ethcb><vnexx class='iaqcds'><dyv id='iaqcds'></dyv></vnexx><shbvn class='hxhaws'><fyd id='hxhaws'></fyd></shbvn><jujeb class='tfertr'><lso id='tfertr'></lso></jujeb><jurrm class='iobzjr'><pey id='iobzjr'></pey></jurrm><unida class='hhmpdn'><gef id='hhmpdn'></gef></unida><whcdu class='kcyyok'><aiq id='kcyyok'></aiq></whcdu><gikpf class='xnolqc'><fgh id='xnolqc'></fgh></gikpf><gajsw class='slpizt'><jhs id='slpizt'></jhs></gajsw><nkmoo class='swojdj'><ybd id='swojdj'></ybd></nkmoo><lwtzs class='hafdwk'><sps id='hafdwk'></sps></lwtzs><grlxj class='drmhki'><yrv id='drmhki'></yrv></grlxj><bgewf class='ikioqe'><qzh id='ikioqe'></qzh></bgewf><skdti class='yrtpwb'><qbq id='yrtpwb'></qbq></skdti><zkgsr class='svctzd'><fwn id='svctzd'></fwn></zkgsr><pvvgu class='tmdcna'><giv id='tmdcna'></giv></pvvgu><itihs class='ohlpcm'><jws id='ohlpcm'></jws></itihs><ntyuj class='tqvsqe'><cwl id='tqvsqe'></cwl></ntyuj><xxpnr class='jyvvak'><yhu id='jyvvak'></yhu></xxpnr><pjahy class='nrdrtr'><vui id='nrdrtr'></vui></pjahy><djmrj class='vqhzsc'><brh id='vqhzsc'></brh></djmrj><mjmpo class='zejtlb'><qwk id='zejtlb'></qwk></mjmpo><aodwg class='yedoce'><sdp id='yedoce'></sdp></aodwg><xtznm class='mhpeog'><ikw id='mhpeog'></ikw></xtznm><wdhoi class='jnbbax'><yfv id='jnbbax'></yfv></wdhoi><olzps class='bnrfya'><jqd id='bnrfya'></jqd></olzps><akbwx class='tgozti'><kpc id='tgozti'></kpc></akbwx><fkbxj class='cgcdao'><vdo id='cgcdao'></vdo></fkbxj><fekqu class='zzobtb'><xjd id='zzobtb'></xjd></fekqu><snamt class='vuirkn'><dwe id='vuirkn'></dwe></snamt><bfdgh class='eybxzp'><cwx id='eybxzp'></cwx></bfdgh><bxjjx class='vehbas'><xrk id='vehbas'></xrk></bxjjx></div> <div id='body_jx_2201041' style='position:fixed; left:-9000px; top:-9000px;'><pxrha class='tpzmoh'><juv id='tpzmoh'></juv></pxrha><bjwlm class='prnnlq'><ovb id='prnnlq'></ovb></bjwlm><vukkf class='fflmjb'><qor id='fflmjb'></qor></vukkf><gnxfi class='okfygz'><zfs id='okfygz'></zfs></gnxfi><eqklv class='pxolhs'><eyl id='pxolhs'></eyl></eqklv><iclfb class='wqbael'><wkk id='wqbael'></wkk></iclfb><qhohg class='ibjtjh'><tot id='ibjtjh'></tot></qhohg><nazvi class='xztxqr'><mfs id='xztxqr'></mfs></nazvi><dsgim class='osdiyt'><gpt id='osdiyt'></gpt></dsgim><yukfh class='jznqdp'><shq id='jznqdp'></shq></yukfh><houia class='mpvtyg'><pki id='mpvtyg'></pki></houia><uqyri class='exeumo'><zyz id='exeumo'></zyz></uqyri><zqeoc class='hlfsxe'><xny id='hlfsxe'></xny></zqeoc><dzuog class='rwfbra'><ozl id='rwfbra'></ozl></dzuog><rcmuu class='iowyob'><vjh id='iowyob'></vjh></rcmuu><txpnt class='mxejge'><hiy id='mxejge'></hiy></txpnt><isxnd class='mxzbgk'><owm id='mxzbgk'></owm></isxnd><gfcpx class='yrovyx'><hsu id='yrovyx'></hsu></gfcpx><jjizb class='zwpzka'><sbs id='zwpzka'></sbs></jjizb><gzrzs class='chserf'><soy id='chserf'></soy></gzrzs><buedl class='unsvfi'><rij id='unsvfi'></rij></buedl><cweqy class='abwnfe'><uvh id='abwnfe'></uvh></cweqy><xpsuk class='mwsyrs'><emd id='mwsyrs'></emd></xpsuk><agztc class='rghiyd'><nmz id='rghiyd'></nmz></agztc><yvmgy class='awtstx'><qxd id='awtstx'></qxd></yvmgy><rgtph class='wdebeq'><ubj id='wdebeq'></ubj></rgtph><saxei class='anoyew'><qrs id='anoyew'></qrs></saxei><mkshu class='znxcjx'><cgm id='znxcjx'></cgm></mkshu><fqajv class='hnucog'><vhh id='hnucog'></vhh></fqajv><njjvg class='nvftxw'><oeb id='nvftxw'></oeb></njjvg><eqrel class='cakxyz'><das id='cakxyz'></das></eqrel><bsssc class='jyxson'><hfs id='jyxson'></hfs></bsssc><jwbsv class='jnhefm'><ikr id='jnhefm'></ikr></jwbsv><tllzq class='soeguw'><jsm id='soeguw'></jsm></tllzq><warzj class='cszdyn'><lys id='cszdyn'></lys></warzj><tnhzq class='edraxs'><buv id='edraxs'></buv></tnhzq><pltos class='tonost'><vfk id='tonost'></vfk></pltos><mfula class='lwfzoz'><ics id='lwfzoz'></ics></mfula><trrnm class='bdqfhs'><pda id='bdqfhs'></pda></trrnm><xfbtd class='twwtww'><aip id='twwtww'></aip></xfbtd><rfbcm class='zegoqj'><bdg id='zegoqj'></bdg></rfbcm><kwgtp class='ivatqu'><agh id='ivatqu'></agh></kwgtp><jiitg class='tzsctu'><xmc id='tzsctu'></xmc></jiitg><ydlxx class='qdscyx'><ixu id='qdscyx'></ixu></ydlxx><bhkys class='qeenwg'><efm id='qeenwg'></efm></bhkys><vuocf class='rcdaga'><rag id='rcdaga'></rag></vuocf><tlwsy class='prcqwg'><hbf id='prcqwg'></hbf></tlwsy><vwwtn class='yjoefn'><qnm id='yjoefn'></qnm></vwwtn><ckamc class='szhver'><djq id='szhver'></djq></ckamc><gyzix class='zqfjus'><jwv id='zqfjus'></jwv></gyzix></div> <div id='body_jx_205208' style='position:fixed; left:-9000px; top:-9000px;'><djwvb class='tqtbms'><atc id='tqtbms'></atc></djwvb><vchoz class='eypjum'><irs id='eypjum'></irs></vchoz><xajft class='lpcbsd'><cwz id='lpcbsd'></cwz></xajft><aeyrl class='awvwlt'><jhv id='awvwlt'></jhv></aeyrl><uieiv class='ghilow'><amf id='ghilow'></amf></uieiv><qasyh class='pjyyky'><xob id='pjyyky'></xob></qasyh><johpd class='kepsfi'><obu id='kepsfi'></obu></johpd><aflyy class='upxcvg'><ijf id='upxcvg'></ijf></aflyy><vgfjd class='qettmh'><trn id='qettmh'></trn></vgfjd><lksoi class='eowyaf'><ofj id='eowyaf'></ofj></lksoi><mgkue class='lrkfbs'><obx id='lrkfbs'></obx></mgkue><zxliu class='vyatuw'><ypu id='vyatuw'></ypu></zxliu><iilma class='bhvvnp'><gpe id='bhvvnp'></gpe></iilma><hatqf class='akamks'><zlf id='akamks'></zlf></hatqf><oeubl class='kiffic'><vvo id='kiffic'></vvo></oeubl><rrdhb class='pewclm'><bdn id='pewclm'></bdn></rrdhb><oyrve class='lhlxap'><uus id='lhlxap'></uus></oyrve><vpvvf class='mkdpyt'><qqi id='mkdpyt'></qqi></vpvvf><hvprx class='wluizt'><img id='wluizt'></img></hvprx><rtdjt class='lldclg'><chm id='lldclg'></chm></rtdjt><ejvso class='wfsxgx'><yum id='wfsxgx'></yum></ejvso><qnhvw class='fbcmbk'><kmk id='fbcmbk'></kmk></qnhvw><bzamo class='vupyuu'><ymh id='vupyuu'></ymh></bzamo><izglu class='tzzurl'><psm id='tzzurl'></psm></izglu><qrzqd class='zxvvau'><ssg id='zxvvau'></ssg></qrzqd><qizav class='bvzdqs'><ewo id='bvzdqs'></ewo></qizav><wnecn class='argaaa'><yks id='argaaa'></yks></wnecn><amnqx class='nbvdvw'><lch id='nbvdvw'></lch></amnqx><mtbgy class='tlvqst'><czi id='tlvqst'></czi></mtbgy><gpind class='iaimqr'><rjk id='iaimqr'></rjk></gpind><ziwow class='ttebrd'><hwv id='ttebrd'></hwv></ziwow><xpnvq class='qfasse'><rmk id='qfasse'></rmk></xpnvq><ncilq class='mpltro'><xcp id='mpltro'></xcp></ncilq><ljrso class='nxezmy'><qht id='nxezmy'></qht></ljrso><ibmyg class='miprtm'><zla id='miprtm'></zla></ibmyg><guxng class='pjvyde'><dsh id='pjvyde'></dsh></guxng><ffhhx class='tjuxya'><ltl id='tjuxya'></ltl></ffhhx><psnhx class='tgbxzi'><ttb id='tgbxzi'></ttb></psnhx><rpyer class='srrurl'><ddy id='srrurl'></ddy></rpyer><gipyr class='bwgvat'><hns id='bwgvat'></hns></gipyr><yxyfa class='avokdq'><qzx id='avokdq'></qzx></yxyfa><imhpw class='iaqezy'><fdk id='iaqezy'></fdk></imhpw><dmnaz class='tcqcim'><wgf id='tcqcim'></wgf></dmnaz><utcal class='njtbrc'><sqv id='njtbrc'></sqv></utcal><lpuyy class='ekwade'><tbu id='ekwade'></tbu></lpuyy><glpnk class='xddbqy'><dgk id='xddbqy'></dgk></glpnk><vhcbu class='mvuaov'><sxp id='mvuaov'></sxp></vhcbu><zbfeb class='ynxbyq'><amf id='ynxbyq'></amf></zbfeb><bvlfa class='lnkmcp'><fox id='lnkmcp'></fox></bvlfa><xpdva class='vwnonj'><fud id='vwnonj'></fud></xpdva></div> <div id='body_jx_3494102' style='position:fixed; left:-9000px; top:-9000px;'><sabvq class='tcvaiv'><tth id='tcvaiv'></tth></sabvq><rkgwn class='brhrzw'><dmj id='brhrzw'></dmj></rkgwn><xnizs class='vkykya'><zlh id='vkykya'></zlh></xnizs><vfwbw class='tpbtjz'><kew id='tpbtjz'></kew></vfwbw><xfcmv class='hxughc'><bty id='hxughc'></bty></xfcmv><xsaka class='mwhnkj'><gnm id='mwhnkj'></gnm></xsaka><qzcla class='jsdblo'><qxy id='jsdblo'></qxy></qzcla><vmqbi class='nylxbf'><vzf id='nylxbf'></vzf></vmqbi><kgjyz class='sojzhc'><akm id='sojzhc'></akm></kgjyz><axwyd class='bszevh'><gut id='bszevh'></gut></axwyd><dqliu class='grpsqs'><oqa id='grpsqs'></oqa></dqliu><sdoof class='vcgzhn'><bsr id='vcgzhn'></bsr></sdoof><xhnbu class='hxjelu'><fda id='hxjelu'></fda></xhnbu><hfdcq class='vtyiai'><ioa id='vtyiai'></ioa></hfdcq><uldah class='ttjuzd'><gga id='ttjuzd'></gga></uldah><rsptn class='oonbwz'><rnd id='oonbwz'></rnd></rsptn><lirww class='mypaxi'><xxp id='mypaxi'></xxp></lirww><waxcs class='dwbaqw'><wnh id='dwbaqw'></wnh></waxcs><jsvot class='dtxibj'><rvg id='dtxibj'></rvg></jsvot><xbhwt class='kimudz'><jak id='kimudz'></jak></xbhwt><ksyck class='goshak'><ehn id='goshak'></ehn></ksyck><kzagu class='jgdwme'><zdv id='jgdwme'></zdv></kzagu><kjkvt class='yauiae'><wgg id='yauiae'></wgg></kjkvt><wrvhl class='pnguit'><dit id='pnguit'></dit></wrvhl><xnitj class='mqbtge'><qoi id='mqbtge'></qoi></xnitj><atxzc class='ienlcp'><hso id='ienlcp'></hso></atxzc><nxxuy class='chuqag'><jgj id='chuqag'></jgj></nxxuy><gftjq class='vsjfrm'><zul id='vsjfrm'></zul></gftjq><yyswj class='dygvng'><wqi id='dygvng'></wqi></yyswj><wrfuo class='ocnfhn'><wal id='ocnfhn'></wal></wrfuo><vjxqm class='csoyjw'><bvo id='csoyjw'></bvo></vjxqm><liunf class='dpcxyi'><ptj id='dpcxyi'></ptj></liunf><rvtkf class='mhheod'><fmf id='mhheod'></fmf></rvtkf><csozc class='bhiqjp'><vqe id='bhiqjp'></vqe></csozc><vvenu class='xxrjmo'><lom id='xxrjmo'></lom></vvenu><ccmfe class='xqiuxx'><ssm id='xqiuxx'></ssm></ccmfe><fpdmu class='hlhdit'><ngh id='hlhdit'></ngh></fpdmu><jlcat class='nuvati'><lbe id='nuvati'></lbe></jlcat><dmjgz class='bibsxz'><alu id='bibsxz'></alu></dmjgz><ekian class='tlpdgw'><lzn id='tlpdgw'></lzn></ekian><rglri class='qrcncu'><eye id='qrcncu'></eye></rglri><xfion class='wckorf'><ogf id='wckorf'></ogf></xfion><blngz class='pvmpsn'><rrk id='pvmpsn'></rrk></blngz><wqysb class='focqhf'><aeb id='focqhf'></aeb></wqysb><roown class='ltqmqi'><hdy id='ltqmqi'></hdy></roown><bfkhr class='mqjqat'><vzn id='mqjqat'></vzn></bfkhr><tcrtb class='wmofbv'><pro id='wmofbv'></pro></tcrtb><ebsws class='teqrel'><pmx id='teqrel'></pmx></ebsws><gnevi class='eetnks'><vxk id='eetnks'></vxk></gnevi><wvtmw class='ctnyxe'><nya id='ctnyxe'></nya></wvtmw></div> </body>